Your browser doesn't support javascript.
loading
Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz, R; García-Alfonso, P; Sobrino, P; Zamora, P; Carrión, R; García-Laraña, J; Pérez, G; López, J; Lavilla, E; Lozano, M; Rayón, C; Colomer, R; Barón, M G; Flores, E; Pérez-Manga, G; Fernández-Rañada, J M.
Afiliação
  • Arranz R; Haematology and Clinical Epidemiology Services, Hospital Universitario de la Princesa, Madrid, Spain. rarranzes@aehh.org
J Clin Oncol ; 16(4): 1538-46, 1998 Apr.
Article em En | MEDLINE | ID: mdl-9580385
ABSTRACT

PURPOSE:

To evaluate the effectiveness of adding interferon (IFN) alfa-2b to chemotherapy in the induction treatment of low-grade non-Hodgkin's lymphoma (NHL), and to assess the role of maintenance IFN. PATIENTS AND

METHODS:

A multicenter, two-phase controlled trial with double randomization was conducted in 155 patients with low-grade NHL. In the first randomization, 78 patients received cyclophosphamide, vincristine, and prednisone (CVP) and IFN, 3 MU/m2 three times a week for 3 months, and 77 patients received CVP alone. Responding patients were randomized to receive IFN for 1 year versus observation.

RESULTS:

Of 144 assessable patients, 73 received CVP + IFN and 71 received CVP. Responses were similar CVP + IFN 79% versus CVP 76% (P = .62). The number of patients who did not complete the treatment was higher in the CVP + IFN group than in the CVP group (18% v 4%; P = .009), although the received dose-intensity of chemotherapy was comparable. Duration of response and progression-free survival (PFS) were significantly higher in the CVP + IFN group than in the CVP group (P = .0004). However, we observed no differences in overall survival (OS) (P = .30), with a median follow-up for the surviving patients of 3 years. Grade 3/4 granulocytopenia was the most frequent toxicity and was similar in both groups (33% v32%). Eighty-three (74%) of the 112 responding patients were randomized to maintenance IFN or observation. The duration of response was similar between 42 patients that received IFN compared with 41 control patients (P = .83), independently of treatment previously administered.

CONCLUSION:

Adding IFN alfa-2b to induction CVP in low-grade NHL did not induce a higher response rate, but it significantly increased the duration of the responses. We found significant differences in PFS that favored the patients who received CVP + IFN, but not in OS. To date, no additional benefit has been seen from the administration of IFN for maintenance.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Interferon-alfa Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Espanha
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Interferon-alfa Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Espanha